Navigation Links
RHEI Pharmaceuticals Appoints Dr. Geert Cauwenbergh as Chief Executive Officer
Date:8/25/2008

008, Dr. Cauwenbergh founded Phases123 LLC, a company focused on identifying high potential health care technology platforms and emerging health care companies. In 2001, Dr. Cauwenbergh founded Barrier Therapeutics, Inc., a company developing novel patented therapeutic agents for treatment of skin diseases. Under his leadership, Barrier Therapeutics went public and raised a total of $250 million in capital, evolving from an R&D organization into a commercial company with expected revenues of $46 to $50 million in 2008, prior to its recent acquisition by Stiefel Laboratories.

Before Barrier Therapeutics, Dr. Cauwenbergh served in numerous positions with Johnson & Johnson (in both the U.S. and Europe), most recently as Vice President of Technology of the Johnson & Johnson (J&J) Consumer and Personal Care Products Companies, and before that, as Vice President of Research & Development of the J&J Consumer Companies Worldwide. Dr. Cauwenbergh was also previously with the R&D organization of the Janssen Research Foundation in Belgium.

Dr. Cauwenbergh currently serves as a Board member of DARA Biosciences, Upstream Biosciences as well as Ablynx NV, and is a member of the Board of Trustees, and Vice Chairman of Bio New Jersey. Since 2004, Dr. Cauwenbergh has served as Official Trade Advisor for Health Care in North America to the Belgian Government. From 2004 to 2006, he served as a member on the Board of Trustees of the New Jersey Center of Life Sciences and from 2003 to 2005, Dr. Cauwenbergh was a member of the Board of Intercept Inc.

Dr. Cauwenbergh has authored over 100 publications and co-authored several books. He received his Ph.D. in Medical Sciences from the Catholic University of Leuven, Faculty of Medicine, where he also completed his Masters and undergraduate work. In 2004 Dr. Cauwenbergh was inducted in the New Jersey High Tech Hall of Fame.

About Asacard(R)

Asacard(R), which RHEI Pharmaceuticals has licensed from Flamel Techn
'/>"/>

SOURCE RHEI Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. VioQuest Pharmaceuticals, Inc Q2/08 Review Issued by Scimitar Equity, LLC
2. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
3. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
4. Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America
5. MicuRx Pharmaceuticals Selects Next-Generation Antibiotic Candidate Targeting MRSA and Expands Operation in China
6. Lotus Pharmaceuticals Announces Second Quarter 2008 Results
7. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
8. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
9. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
10. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
11. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... SAN DIEGO , June 29, 2015 ... a group of top research institutes, announced today that ... at Mount Sinai resulted in the creation of the ... two complementary single DNA molecule methods for sequencing and ... Methods , provided the comprehensive analysis of the contiguous ...
(Date:6/29/2015)... St. Louis, MO (PRWEB) , ... June 29, 2015 , ... ... July 15 – July 16 and for the fourth year in a row, will ... on what changes are taking place at the intersection of data and technology. The ...
(Date:6/26/2015)... , June 26, 2015   ... ), a pet therapeutics company focused on ... biopharmaceutical products for companion animals, today announced ... study of capromorelin (AT-002), the company,s innovative ... is a small molecule that mimics ghrelin, ...
(Date:6/26/2015)... ... June 26, 2015 , ... ... its SimplePrep™ technologies have been integrated into a sample prep module intended to ... as a part of the NASA’s WetLab-2 Project. , On June 28, 2015, ...
Breaking Biology Technology:BioNano Mapping Technology Achieves Most Contiguous Clone-free Human Genome Assembly to Date 2BioNano Mapping Technology Achieves Most Contiguous Clone-free Human Genome Assembly to Date 3StampedeCon Announces 2015 Agenda 2StampedeCon Announces 2015 Agenda 3Aratana Therapeutics Announces Positive Pivotal Results for AT-002 2Aratana Therapeutics Announces Positive Pivotal Results for AT-002 3Aratana Therapeutics Announces Positive Pivotal Results for AT-002 4Aratana Therapeutics Announces Positive Pivotal Results for AT-002 5Claremont BioSolutions’ SimplePrep™ Products Deployed in NASA Wetlab-2 Project Slated for June 28th Flight to International Space Station aboard SpaceX CRS-7 2Claremont BioSolutions’ SimplePrep™ Products Deployed in NASA Wetlab-2 Project Slated for June 28th Flight to International Space Station aboard SpaceX CRS-7 3
... ... CUNY Nobel Science Challenge. , ... New York, NY (Vocus) March 12, 2010 -- Borough of Manhattan Community College (BMCC) ... 2009 CUNY Nobel Science Challenge—as well as $5,000 as an overall Grand Prizewinner., , , ...
... Food and Drug Administration (FDA) has approved a five-day dosing regimen for Dacogen® (decitabine) for Injection to treat patients with myelodysplastic syndromes (MDS), a group of ... ... , ... ...
... ... , ... ... EDMONTON , March 11 /PRNewswire/ - Today at ACAMP,s ...
Cached Biology Technology:BMCC Student—the Only Community College Winner—Lands Grand Prize in Nobel Science Challenge 2FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 2FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 3FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 4FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 5FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 6FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 7FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 8Alberta companies delivering new products to the Conventional Energy marketplace 2Alberta companies delivering new products to the Conventional Energy marketplace 3
(Date:6/25/2015)...  Imagine a tool specifically designed to help you ... That,s exactly what USANA,s True Health Assessment ... health program provides a personalized approached to measuring your ... lifestyle and nutrition. At the Canadian ... USANA,s THA was honored with the Industry Innovation Award. ...
(Date:6/24/2015)... -- The biologics safety testing market is growing at ... include growth of the pharmaceutical and biological industries and ... years, the number of drug approvals in North American ... approved 225 drug applications and Health Canada approved 99. ... accounted for 3,822 of the pharmaceutical and 1,998 ...
(Date:6/24/2015)... , June 24, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced that Sharp has selected ... secure authentication for its latest flagship smartphone device, ... than 200 million shipments of its fingerprint ID ... Synaptics, strength, scalability and leadership in the biometrics ...
Breaking Biology News(10 mins):@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2
... causing urinary tract infections (UTIs), the second-most-common infection in ... with current antibiotics, according to new research from Extending ... Disease Dynamics, Economics & Policy. ETC released the ... to track changes in antibiotic drug use and resistance. ...
... Nov. 13, 2012 Millions of laboratory tests and ... processes. Quantum Materials Corporation has now developed tetrapod ... gain knowledge of how body systems function and chronic ... health and longevity. Conventionally, fluorescent tags or ...
... $15,000 in a national competition for adapting a traditional ... villagers can use to make paper for their children,s ... of a machine to convert farm waste to paper, ... Houston during a ceremony honoring top submissions in the ...
Cached Biology News:Second most common infection in the US proving harder to treat with current antibiotics 2Second most common infection in the US proving harder to treat with current antibiotics 3Second most common infection in the US proving harder to treat with current antibiotics 4High Brightness Tetrapod Quantum Dots Developed 2High Brightness Tetrapod Quantum Dots Developed 3Plan to turn farm waste into paper earns students $15,000 2
... smallest electronic pressure controller available measuring 26 ... this unit specifically for the analytical instrumentation ... carrier gas flow control, microfluidic flow control, ... focusing, the OEM-EPC offers external pressure sensor ...
... Flow) offers the same benefits as the VSO ... control is critical or flow is required below ... flow of gas in proportion to the input ... pulse width modulation; closed loop feedback delivers optimal ...
...
... Serum is obtained from non-demolished ... healthy, fasted donors. The donors ... way and are maintained on ... Total Protein Concentration : 85 ...
Biology Products: